Developer docs
API playgroundTry for free, no card

Search company profiles

Daiichi Sankyo UK

Full company profile

uuid000csqf

Namestring
Daiichi Sankyo UK
Legal namestring
Daiichi Sankyo UK Ltd
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Daiichi Sankyo UK Ltd is a privately held UK pharmaceutical affiliate of Japan's Daiichi Sankyo Co. Ltd., headquartered at Uxbridge Business Park and operating since its 2006 founding. The company develops, registers, and supplies prescription medicines to the NHS in two therapeutic areas: cardiovascular disease (hypertension treatments Olmetec, Olmetec Plus, Sevikar and Sevikar HCT; anticoagulant Lixiana/edoxaban; lipid-lowering agents Nilemdo/bempedoic acid and Nustendi/bempedoic acid plus ezetimibe) and oncology (Enhertu/trastuzumab deruxtecan for HER2-expressing cancers; Vanflyta/quizartinib for acute myeloid leukaemia). The portfolio is delivered as finished-dose formulations developed and manufactured through the parent group's global production network, including a major plant in Pfaffenhofen, Germany, with no UK-based manufacturing disclosed.

The business monetises through standard pharmaceutical commercialisation channels: field sales representatives engage NHS clinicians, pharmacists, primary care networks, and hospital trusts to drive prescribing, while formal collaborative and joint-working projects with named NHS organisations (FIND-AF atrial fibrillation detection, Capture AF, MDT Lipid Clinic optimisation, post-coronary re-vascularisation lipid services) aim to improve patient pathways in cardiovascular care. Pricing for prescription products is not publicly disclosed; access is mediated through NHS reimbursement and prescribing frameworks, with adverse-event reporting, medical information, and pharmacovigilance handled through dedicated UK contact channels.

As a wholly-owned subsidiary of a Tokyo-headquartered global group with more than 100 years of scientific heritage, a presence in over 20 countries, and roughly 2,500 European employees across 14 countries plus Canada, Daiichi Sankyo UK inherits the parent's R&D pipeline, regulatory filings, and brand equity while operating with UK-specific compliance, transparency (Disclosure UK), and ABPI Code of Practice alignment. Its headcount sits in the 251-500 range, and its go-to-market is enterprise field sales directed at NHS and private healthcare customers, supported by digital channels (corporate website, LinkedIn, X) and a parliamentary-level policy advocacy posture anchored by the 'Accelerating Ambition' programme.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersUxbridge, United Kingdom
HQ citystring
Uxbridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular pharmaceuticals, oncology medicines, prescription drugs, anticoagulant therapy, lipid management
Industry2 codes
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Prescription Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Daiichi Sankyo UK generates revenue through the sale of prescription medicines to the NHS, healthcare providers, and pharmacies in the cardiovascular and oncology therapeutic areas.

daiichi-sankyo.co.uk
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Daiichi Sankyo UK Ltd is the UK affiliate of the Japanese pharmaceutical group Daiichi Sankyo. It develops and supplies innovative prescription medicines in two principal therapeutic areas — cardiovascular disease (hypertension, anticoagulation, lipid management) and oncology (HER2-positive cancers, acute myeloid leukaemia). Products are marketed and distributed to the NHS, healthcare professionals, and pharmacies across the United Kingdom.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Daiichi Sankyo UK is a pharmaceutical company that creates and supplies innovative prescription medicines. The company operates in two primary therapeutic areas: cardiovascular disease (including hypertension, hypercholesterolaemia, and anticoagulation) and oncology. The product portfolio consists of prescription-only medicines including Enhertu (oncology), Lixiana (anticoagulant), Nilemdo and Nustendi (lipid-lowering), and the Olmetec and Sevikar families of antihypertensive medications (including combination formulations with diuretics and calcium channel blockers), plus Vanflyta (oncology). These are marketed to NHS healthcare professionals and patients in the UK.

Product and service11 records
1Enhertu (trastuzumab deruxtecan)
CategoryPrescription pharmaceutical product
Description

A prescription oncology medicine for the treatment of HER2-positive breast cancer and other HER2-expressing or HER2-mutant cancers, supplied to NHS hospitals and oncology specialists.

2Lixiana (edoxaban tosilate)
CategoryPrescription pharmaceutical product
Description

An oral anticoagulant (Factor Xa inhibitor) prescribed to prevent and treat blood clots, including stroke prevention in atrial fibrillation and treatment of venous thromboembolism.

3Nilemdo (bempedoic acid)
CategoryPrescription pharmaceutical product
Description

A lipid-lowering prescription medicine used to treat hypercholesterolaemia in patients unable to tolerate statins or requiring additional LDL-cholesterol reduction.

4Nustendi (bempedoic acid, ezetimibe)
CategoryPrescription pharmaceutical product
Description

A combination lipid-lowering prescription medicine containing bempedoic acid and ezetimibe for patients with hypercholesterolaemia requiring additional LDL-cholesterol lowering.

5Olmetec (olmesartan medoximil)
CategoryPrescription pharmaceutical product
Description

An angiotensin II receptor blocker (ARB) prescribed for the treatment of essential hypertension.

6Olmetec Plus 20 mg/12.5 mg (olmesartan medoximil, hydrochlorothiazide)
CategoryPrescription pharmaceutical product (combination)
Description

A combination antihypertensive prescription medicine pairing an ARB with a thiazide diuretic for the treatment of essential hypertension.

7Olmetec Plus 40 mg/12.5 mg (olmesartan medoximil, hydrochlorothiazide)
CategoryPrescription pharmaceutical product (combination)
Description

A higher-dose combination antihypertensive prescription medicine pairing an ARB with a thiazide diuretic for the treatment of essential hypertension.

8Sevikar (olmesartan medoximil, amlodipine besilate)
CategoryPrescription pharmaceutical product (combination)
Description

A combination antihypertensive prescription medicine pairing an ARB with a calcium channel blocker for the treatment of essential hypertension.

9Sevikar HCT (olmesartan medoximil, amlodipine besilate, hydrochlorothiazide)
CategoryPrescription pharmaceutical product (combination)
Description

A triple-combination antihypertensive prescription medicine combining an ARB, a calcium channel blocker and a thiazide diuretic for the treatment of essential hypertension.

10Vanflyta 17.7 mg (quizartinib)
CategoryPrescription pharmaceutical product
Description

A prescription oncology medicine for the treatment of acute myeloid leukaemia (AML), supplied to NHS hospitals and oncology specialists.

11Vanflyta 26.5 mg (quizartinib)
CategoryPrescription pharmaceutical product
Description

A higher-dose prescription oncology medicine for the treatment of acute myeloid leukaemia (AML), supplied to NHS hospitals and oncology specialists.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthers
Description

IQVIA provides master and address data (name, title, company information, professional addresses, employment details, area of expertise and specialisation) to Daiichi Sankyo UK for obtaining relevant HCP contacts in business areas of interest and ensuring data quality.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-headquartered major pharmaceutical company with cardiovascular and oncology specialty franchises; comparable NHS enterprise commercial operations.

TypeDirect peer
Description

Major oncology competitor (HER2 franchise including Herceptin, Kadcyla, Phesgo) and broader UK specialty pharma presence; comparable NHS oncology engagement.

TypeBroad incumbent
Description

Specialty biotech with UK cardiovascular (Repatha for LDL-C lowering) and oncology presence; competes in adjacent cardiovascular and specialty spaces.

4Sanofi UK
TypeDirect peer
Description

Multinational pharma with cardiovascular (Praluent for lipid management) and specialty/oncology assets; comparable UK enterprise pharma commercial model.

TypeDirect peer
Description

Specialty pharma company with strong UK oncology franchise (Kisqali, Kymriah, radioligand therapy) and cardiovascular heritage; comparable scale and NHS engagement model.

6Bristol Myers Squibb UK
TypeDirect peer
Description

Direct competitor in DOAC anticoagulation via Eliquis (apixaban) and a strong oncology portfolio; comparable NHS-facing cardiovascular/oncology mix.

TypeDirect peer
Description

Multinational pharma operating in UK cardiovascular (anticoagulants Xarelto, hypertension franchise) and oncology; highly comparable product-level competition and NHS sales model.

8Boehringer Ingelheim UK
TypeDirect peer
Description

Direct DOAC competitor (Pradaxa/dabigatran) and cardiovascular franchise; comparable specialty pharma positioning in UK NHS.

TypeDirect peer
Description

Major multinational pharma with significant UK cardiovascular and oncology presence; comparable specialty pharma portfolio and NHS enterprise sales model.

TypeDirect peer
Description

UK-domiciled major pharmaceutical company with deep cardiovascular (e.g. Brilinta, Crestor legacy) and oncology (Enhertu's co-development partner) portfolios; directly comparable therapeutic-area mix and NHS-facing commercial model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Daiichi Sankyo UK

Prescription Pharmaceuticalsdaiichi-sankyo.co.uk

What Daiichi Sankyo UK does

Daiichi Sankyo UK Ltd is a privately held UK pharmaceutical affiliate of Japan's Daiichi Sankyo Co. Ltd., headquartered at Uxbridge Business Park and operating since its 2006 founding. The company develops, registers, and supplies prescription medicines to the NHS in two therapeutic areas: cardiovascular disease (hypertension treatments Olmetec, Olmetec Plus, Sevikar and Sevikar HCT; anticoagulant Lixiana/edoxaban; lipid-lowering agents Nilemdo/bempedoic acid and Nustendi/bempedoic acid plus ezetimibe) and oncology (Enhertu/trastuzumab deruxtecan for HER2-expressing cancers; Vanflyta/quizartinib for acute myeloid leukaemia). The portfolio is delivered as finished-dose formulations developed and manufactured through the parent group's global production network, including a major plant in Pfaffenhofen, Germany, with no UK-based manufacturing disclosed.

The business monetises through standard pharmaceutical commercialisation channels: field sales representatives engage NHS clinicians, pharmacists, primary care networks, and hospital trusts to drive prescribing, while formal collaborative and joint-working projects with named NHS organisations (FIND-AF atrial fibrillation detection, Capture AF, MDT Lipid Clinic optimisation, post-coronary re-vascularisation lipid services) aim to improve patient pathways in cardiovascular care. Pricing for prescription products is not publicly disclosed; access is mediated through NHS reimbursement and prescribing frameworks, with adverse-event reporting, medical information, and pharmacovigilance handled through dedicated UK contact channels.

As a wholly-owned subsidiary of a Tokyo-headquartered global group with more than 100 years of scientific heritage, a presence in over 20 countries, and roughly 2,500 European employees across 14 countries plus Canada, Daiichi Sankyo UK inherits the parent's R&D pipeline, regulatory filings, and brand equity while operating with UK-specific compliance, transparency (Disclosure UK), and ABPI Code of Practice alignment. Its headcount sits in the 251-500 range, and its go-to-market is enterprise field sales directed at NHS and private healthcare customers, supported by digital channels (corporate website, LinkedIn, X) and a parliamentary-level policy advocacy posture anchored by the 'Accelerating Ambition' programme.

Daiichi Sankyo UK firmographics

Firmographics
Name
Daiichi Sankyo UK
Legal name
Daiichi Sankyo UK Ltd
Website
https://daiichi-sankyo.co.uk
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Daiichi Sankyo UK industry classification

Industry
Product category
Prescription Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Cardiovascular pharmaceuticals
  • Oncology medicines
  • Prescription drugs
  • Anticoagulant therapy
  • Lipid management

Where Daiichi Sankyo UK is headquartered

Location

Headquarters

HQ city
Uxbridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Daiichi Sankyo UK business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Daiichi Sankyo UK generates revenue through the sale of prescription medicines to the NHS, healthcare providers, and pharmacies in the cardiovascular and oncology therapeutic areas.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Daiichi Sankyo UK product offering

Product offering

Core offering

Daiichi Sankyo UK Ltd is the UK affiliate of the Japanese pharmaceutical group Daiichi Sankyo. It develops and supplies innovative prescription medicines in two principal therapeutic areas — cardiovascular disease (hypertension, anticoagulation, lipid management) and oncology (HER2-positive cancers, acute myeloid leukaemia). Products are marketed and distributed to the NHS, healthcare professionals, and pharmacies across the United Kingdom.

Product overview

Daiichi Sankyo UK is a pharmaceutical company that creates and supplies innovative prescription medicines. The company operates in two primary therapeutic areas: cardiovascular disease (including hypertension, hypercholesterolaemia, and anticoagulation) and oncology. The product portfolio consists of prescription-only medicines including Enhertu (oncology), Lixiana (anticoagulant), Nilemdo and Nustendi (lipid-lowering), and the Olmetec and Sevikar families of antihypertensive medications (including combination formulations with diuretics and calcium channel blockers), plus Vanflyta (oncology). These are marketed to NHS healthcare professionals and patients in the UK.

Differentiator

Problem solved

Functional benefit

Products and services

  • Enhertu (trastuzumab deruxtecan) A prescription oncology medicine for the treatment of HER2-positive breast cancer and other HER2-expressing or HER2-mutant cancers, supplied to NHS hospitals and oncology specialists.
  • Lixiana (edoxaban tosilate) An oral anticoagulant (Factor Xa inhibitor) prescribed to prevent and treat blood clots, including stroke prevention in atrial fibrillation and treatment of venous thromboembolism.
  • Nilemdo (bempedoic acid) A lipid-lowering prescription medicine used to treat hypercholesterolaemia in patients unable to tolerate statins or requiring additional LDL-cholesterol reduction.
  • Nustendi (bempedoic acid, ezetimibe) A combination lipid-lowering prescription medicine containing bempedoic acid and ezetimibe for patients with hypercholesterolaemia requiring additional LDL-cholesterol lowering.
  • Olmetec (olmesartan medoximil) An angiotensin II receptor blocker (ARB) prescribed for the treatment of essential hypertension.
  • Olmetec Plus 20 mg/12.5 mg (olmesartan medoximil, hydrochlorothiazide) A combination antihypertensive prescription medicine pairing an ARB with a thiazide diuretic for the treatment of essential hypertension.
  • Olmetec Plus 40 mg/12.5 mg (olmesartan medoximil, hydrochlorothiazide) A higher-dose combination antihypertensive prescription medicine pairing an ARB with a thiazide diuretic for the treatment of essential hypertension.
  • Sevikar (olmesartan medoximil, amlodipine besilate) A combination antihypertensive prescription medicine pairing an ARB with a calcium channel blocker for the treatment of essential hypertension.
  • Sevikar HCT (olmesartan medoximil, amlodipine besilate, hydrochlorothiazide) A triple-combination antihypertensive prescription medicine combining an ARB, a calcium channel blocker and a thiazide diuretic for the treatment of essential hypertension.
  • Vanflyta 17.7 mg (quizartinib) A prescription oncology medicine for the treatment of acute myeloid leukaemia (AML), supplied to NHS hospitals and oncology specialists.
  • Vanflyta 26.5 mg (quizartinib) A higher-dose prescription oncology medicine for the treatment of acute myeloid leukaemia (AML), supplied to NHS hospitals and oncology specialists.

Companies that use Daiichi Sankyo UK

Customer profile

Named customers13 records

Segments4 records

Ideal customer profiles2 records

Daiichi Sankyo UK technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Daiichi Sankyo UK partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • IQVIA Operations France SASminorOthersIQVIA provides master and address data (name, title, company information, professional addresses, employment details, area of expertise and specialisation) to Daiichi Sankyo UK for obtaining relevant HCP contacts in business areas of interest and ensuring data quality.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Daiichi Sankyo UK competitors and assessment

Company assessment

Direct peers

  • GSK UK: UK-headquartered major pharmaceutical company with cardiovascular and oncology specialty franchises; comparable NHS enterprise commercial operations.
  • Roche UK: Major oncology competitor (HER2 franchise including Herceptin, Kadcyla, Phesgo) and broader UK specialty pharma presence; comparable NHS oncology engagement.
  • Sanofi UK: Multinational pharma with cardiovascular (Praluent for lipid management) and specialty/oncology assets; comparable UK enterprise pharma commercial model.
  • Novartis UK: Specialty pharma company with strong UK oncology franchise (Kisqali, Kymriah, radioligand therapy) and cardiovascular heritage; comparable scale and NHS engagement model.
  • Bristol Myers Squibb UK: Direct competitor in DOAC anticoagulation via Eliquis (apixaban) and a strong oncology portfolio; comparable NHS-facing cardiovascular/oncology mix.
  • Bayer UK: Multinational pharma operating in UK cardiovascular (anticoagulants Xarelto, hypertension franchise) and oncology; highly comparable product-level competition and NHS sales model.
  • Boehringer Ingelheim UK: Direct DOAC competitor (Pradaxa/dabigatran) and cardiovascular franchise; comparable specialty pharma positioning in UK NHS.
  • Pfizer UK: Major multinational pharma with significant UK cardiovascular and oncology presence; comparable specialty pharma portfolio and NHS enterprise sales model.
  • AstraZeneca UK: UK-domiciled major pharmaceutical company with deep cardiovascular (e.g. Brilinta, Crestor legacy) and oncology (Enhertu's co-development partner) portfolios; directly comparable therapeutic-area mix and NHS-facing commercial model.

Broad incumbents

  • Amgen UK: Specialty biotech with UK cardiovascular (Repatha for LDL-C lowering) and oncology presence; competes in adjacent cardiovascular and specialty spaces.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Daiichi Sankyo UK social profiles

Digital presence

Daiichi Sankyo UK financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Daiichi Sankyo UK leadership team

Management profile

Number of profiles

Profiles1 record

Daiichi Sankyo UK funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Daiichi Sankyo UK M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Daiichi Sankyo UK

What does Daiichi Sankyo UK do?

Daiichi Sankyo UK Ltd is the UK affiliate of the Japanese pharmaceutical group Daiichi Sankyo. It develops and supplies innovative prescription medicines in two principal therapeutic areas — cardiovascular disease (hypertension, anticoagulation, lipid management) and oncology (HER2-positive cancers, acute myeloid leukaemia). Products are marketed and distributed to the NHS, healthcare professionals, and pharmacies across the United Kingdom.

Is Daiichi Sankyo UK a public or private company?

Daiichi Sankyo UK is a private company. It is classified as corporate owned and is currently operating.

When was Daiichi Sankyo UK founded?

Daiichi Sankyo UK was founded in 2006. It employs 101 to 250 people.

Where is Daiichi Sankyo UK based?

Daiichi Sankyo UK is headquartered in Uxbridge, United Kingdom, in the Europe region.

How does Daiichi Sankyo UK make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Daiichi Sankyo UK's main competitors?

Direct peers on record are GSK UK, Roche UK, Sanofi UK, Novartis UK, Bristol Myers Squibb UK, Bayer UK, Boehringer Ingelheim UK, Pfizer UK and AstraZeneca UK. Amgen UK is listed as a broad incumbent.

Does Daiichi Sankyo UK have an API?

No public API is recorded for Daiichi Sankyo UK.

What industry is Daiichi Sankyo UK in?

Daiichi Sankyo UK's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAAAAAL, Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales